Tg Therapeutics Stock Revenue
| TGTX Stock | USD 41.06 0.22 0.54% |
TG Therapeutics fundamentals help investors to digest information that contributes to TG Therapeutics' financial success or failures. It also enables traders to predict the movement of TGTX Stock. The fundamental analysis module provides a way to measure TG Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TG Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 329 M | 345.5 M |
TGTX | Revenue |
TG Therapeutics Company Revenue Analysis
TG Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current TG Therapeutics Revenue | 329 M |
Most of TG Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TG Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of TGTX
Projected quarterly revenue analysis of TG Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of TG Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in TG Therapeutics' stock price.
TGTX Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for TG Therapeutics is extremely important. It helps to project a fair market value of TGTX Stock properly, considering its historical fundamentals such as Revenue. Since TG Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of TG Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of TG Therapeutics' interrelated accounts and indicators.
| 0.17 | -0.17 | 0.08 | -0.09 | -0.1 | ||
| 0.17 | 0.0 | -0.27 | -0.12 | 0.46 | ||
| -0.17 | 0.0 | 0.07 | -0.19 | 0.17 | ||
| 0.08 | -0.27 | 0.07 | -0.13 | -0.49 | ||
| -0.09 | -0.12 | -0.19 | -0.13 | 0.25 | ||
| -0.1 | 0.46 | 0.17 | -0.49 | 0.25 |
Click cells to compare fundamentals
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
TGTX Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, TG Therapeutics reported 329 M of revenue. This is 95.69% lower than that of the Biotechnology sector and 55.71% lower than that of the Health Care industry. The revenue for all United States stocks is 96.51% higher than that of the company.
TGTX Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TG Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TG Therapeutics could also be used in its relative valuation, which is a method of valuing TG Therapeutics by comparing valuation metrics of similar companies.TG Therapeutics is currently under evaluation in revenue category among its peers.
TG Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of TG Therapeutics from analyzing TG Therapeutics' financial statements. These drivers represent accounts that assess TG Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of TG Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 980.9M | 6.0B | 1.6B | 2.4B | 4.4B | 4.6B | |
| Enterprise Value | 909.1M | 5.5B | 1.6B | 2.4B | 4.4B | 4.7B |
TG Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, TG Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to TG Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
TG Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in TG Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of TG Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing TG Therapeutics' value.| Shares | Goldman Sachs Group Inc | 2024-12-31 | 1.6 M | Northern Trust Corp | 2024-12-31 | 1.5 M | Hood River Capital Management Llc | 2024-12-31 | 1.5 M | Charles Schwab Investment Management Inc | 2024-12-31 | 1.3 M | Fmr Inc | 2024-12-31 | 1 M | Amvescap Plc. | 2024-12-31 | 929.7 K | Bank Of New York Mellon Corp | 2024-12-31 | 923.5 K | Principal Financial Group Inc | 2024-12-31 | 830.2 K | Susquehanna International Group, Llp | 2024-12-31 | 827.1 K | Blackrock Inc | 2024-12-31 | 21.9 M | Vanguard Group Inc | 2024-12-31 | 15.6 M |
TGTX Fundamentals
| Return On Equity | 0.12 | ||||
| Return On Asset | 0.0578 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 6.36 B | ||||
| Shares Outstanding | 157.07 M | ||||
| Shares Owned By Insiders | 9.41 % | ||||
| Shares Owned By Institutions | 62.69 % | ||||
| Number Of Shares Shorted | 25.74 M | ||||
| Price To Earning | (4.14) X | ||||
| Price To Book | 28.85 X | ||||
| Price To Sales | 19.50 X | ||||
| Revenue | 329 M | ||||
| Gross Profit | 290.52 M | ||||
| EBITDA | 49.9 M | ||||
| Net Income | 23.38 M | ||||
| Cash And Equivalents | 195.71 M | ||||
| Cash Per Share | 1.45 X | ||||
| Total Debt | 253.72 M | ||||
| Debt To Equity | 0.62 % | ||||
| Current Ratio | 4.68 X | ||||
| Book Value Per Share | 1.54 X | ||||
| Cash Flow From Operations | (40.52 M) | ||||
| Short Ratio | 14.83 X | ||||
| Earnings Per Share | 0.15 X | ||||
| Target Price | 42.83 | ||||
| Number Of Employees | 338 | ||||
| Beta | 2.3 | ||||
| Market Capitalization | 6.41 B | ||||
| Total Asset | 577.69 M | ||||
| Retained Earnings | (1.53 B) | ||||
| Working Capital | 475.68 M | ||||
| Current Asset | 71.33 M | ||||
| Current Liabilities | 16.88 M | ||||
| Net Asset | 577.69 M |
About TG Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TG Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TG Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TG Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for TGTX Stock Analysis
When running TG Therapeutics' price analysis, check to measure TG Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TG Therapeutics is operating at the current time. Most of TG Therapeutics' value examination focuses on studying past and present price action to predict the probability of TG Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TG Therapeutics' price. Additionally, you may evaluate how the addition of TG Therapeutics to your portfolios can decrease your overall portfolio volatility.